Key updates from SABCS 2024 in early breast cancer include the COMET study on DCIS recurrence, INSEMA trial on SLNB omission, and OlympiA updates on adjuvant olaparib, shared by Dr Harold Burstein.

Study reveals short term safety of active monitoring for ductal carcinoma in situ. ScienceDaily . Retrieved January 9, 2025 from www.sciencedaily.com / releases / 2024 / 12 / 241212115836.htm ...

Women with Stage 0 breast cancer who got biannual mammograms and delayed surgery for two years fared as well as those who got immediate surgery.

Ductal carcinoma in situ (DCIS) is an early form of cancer confined to the lactiferous (milk producing) ducts of the breast. The choice of whether surgery is required or what surgery is best for you ...

Inside Edition’ reporter Alison Hall says Olivia Munn deciding to share her cancer diagnosis helped save her life ...

Each year, more than 56,500 women are diagnosed with ductal carcinoma in situ (DCIS), a non-invasive type of breast cancer commonly referred to as Stage 0 breast cancer. A woman with DCIS is ...

AI-supported mammography screening significantly increases breast cancer detection rates while maintaining comparable recall ...

“All current treatments for DCIS aim to reduce the risk of future invasive cancer, despite a growing body of evidence that not all DCIS is destined to progress,” said Dr. Shelley Hwang, a professor of ...

Perspective from Eleonora Teplinsky, MD SAN ANTONIO — Certain patients with low-risk ductal carcinoma can safely opt for active monitoring, according to study results presented at San Antonio ...

More information: Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ A Secondary Analysis of the COMET Randomized Clinical Trial, JAMA Oncology (2024). DOI: 10.1001/jamaoncol.2024.6556 ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN ANTONIO -- Active monitoring for low-risk ductal carcinoma in situ (DCIS) did not lead to a higher rate of ...

Over the last decade, it has become widely accepted that there is indeed considerable overdiagnosis of both ductal carcinoma in situ and invasive breast cancer. As many as one in three breast ...